Stifel maintains USD 9.00 target for Senseonics stock

Published on 10/17/2026 at 19:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue in 2026's second quarter reached USD 14.48 million. Senseonics stock was USD 7.77 on October 16, 2026, down 5.59 percent versus Nasdaq's prior close.

Analyst view and operating scale

Stifel Nicolaus maintained its USD 9.00 target on October 8, 2026.
Revenue in the second quarter of 2026 reached USD 14.48 million, up 117.74 percent year over year.
Senseonics stock was USD 7.77 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 5.59 percent versus the prior close.
Senseonics had a USD 410.8 million market capitalization and a price-to-earnings ratio of minus 3.42 on October 16, 2026.

SENS, US81727U3032, Illustration mit AI erstellt.

On October 8, 2026, Stifel Nicolaus maintained a Hold rating and a USD 9.00 target for Senseonics, 15.83 percent above the October 16 Nasdaq price of USD 7.77, according to Markets Insider. Senseonics last traded at USD 7.77 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 5.59 percent versus the prior close.

Revenue growth meets a deep loss

For the quarter ended June 30, 2026, GAAP revenue reached USD 14.48 million, up 117.74 percent from USD 6.65 million in the second quarter of 2025. GAAP net loss widened to USD 36.71 million from USD 14.50 million a year earlier, according to Markets Insider. The company develops implantable continuous glucose monitoring systems, including Eversense, for people managing diabetes, as described by Senseonics.

Price position and trading activity

On October 16, 2026, the Nasdaq session showed a day range of USD 7.75 to USD 8.23. Volume was 608,476 shares against an average of 689,264, leaving activity 11.72 percent below the average. The 52-week range was USD 4.79 to USD 10.64, placing the last price 26.97 percent below the high and 62.21 percent above the low.

Valuation remains tied to execution

Senseonics had a USD 410.8 million market capitalization and a price-to-earnings ratio of minus 3.42 on October 16, 2026. The negative ratio reflects the company's reported loss rather than a positive earnings base. Stifel's USD 9.00 target leaves a 15.83 percent gap above the latest Nasdaq price, while the broader analyst picture includes targets of USD 10.00 from Barclays and USD 15.00 from TD Cowen in October and September 2026, respectively.

Comparison with peers

The October 16, 2026 session comparison places Senseonics beside larger medical-device companies.

Senseonics (Nasdaq, USD): minus 5.59 percent, P/E minus 3.42, market capitalization USD 410.8 million

DexCom (Nasdaq, USD): minus 1.90 percent, P/E 34.01, market capitalization USD 32.5 billion

Abbott Laboratories (NYSE, USD): plus 0.19 percent, P/E 33.72, market capitalization USD 181.5 billion

Stock closes the week in focus

Senseonics combines rapid quarterly revenue growth with a large reported loss, leaving execution and the commercial adoption of Eversense central to the stock's valuation. The October 16 decline also left the shares materially below their 52-week high.